All posts

Press release

Avenue Biosciences Selected for 2025 BioTools Innovator Accelerator Program

June 11, 2025 1:14 PM

Palo Alto, CA – June 11, 2025 – BioTools Innovator Accelerator is the first and only program focused exclusively on life science tools and diagnostics companies. Avenue Biosciences is proud to be among the 31 companies selected to the 2025 BioTools Innovator Accelerator program from over 400 applicants.

Becoming a member of the BioTools Innovator community provides support and resources for developing novel tools that accelerate biologics production and development.

Avenue Biosciences’ first-to-market protein engineering technology employs a high throughput approach to optimize signal peptides and maximize protein expression. The technology has a broad applicability across mRNA therapies, gene therapy vectors, antibody engineering, biosimilars, de novo proteins and more.

BioTools Innovator Accelerator in short:

  • A prestigious, four-month accelerator program offering tailored mentorship from senior industry leaders, investor exposure, and networking opportunities.
  • Chosen from a highly competitive pool of more than 400 applicants, the selected companies represent the top 7% of applicants.
  • At the end of the program, companies will compete for $300,000 in non-dilutive cash prizes.

Read BTI Press release here.

About Avenue Biosciences

Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Based inSan Francisco, USA, and Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biology and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. www.avenuebiosciences.com

About BioTools Innovator

BioTools Innovator, based in Los Angeles, advances cutting-edge research and improves human health by accelerating the growth of life science tools and diagnostics startups. Powered by MedTech Innovator, the world’s largest accelerator for medical technology companies, BTI supports early-stage and emerging growth companies through mentorship, visibility, and non-dilutive funding opportunities. Learn more at https://biotoolsinnovator.org.

 

CEO Tero-Pekka Alastalo in San Diego. Credit: BioTools Innovator.

News

PRESS RELEASE

Stay informed: Announcements, key milestones, and what we are working on next.

June 11, 2025

Avenue Biosciences Selected for 2025 BioTools Innovator Accelerator Program

Read more
Avenue Biosciences Selected for 2025 BioTools Innovator Accelerator Program

May 20, 2025

Veli-Pekka Jaakola joins Avenue Biosciences as Chief Technology Officer

Read more
Veli-Pekka Jaakola joins Avenue Biosciences as Chief Technology Officer

October 22, 2024

Avenue Biosciences Raises $2.5M Seed to Scale AI-Enhanced Protein Engineering

Read more
Avenue Biosciences Raises $2.5M Seed to Scale AI-Enhanced Protein Engineering

Media kit

Access

Contact

Communications Director Juulia Simonen

Email

juulia.simonen@avenuebiosciences.com

Phone

+358503059018
Machine learning and faster discovery in biotechnology.

revolutionizing healthcare through innovative solutions

Discover our cutting-edge technology and services that drive advancements in biopharma.

Contact
Services